HC Wainwright & Co. Maintains Buy on BiomX, Lowers Price Target to $10
HC Wainwright & Co. analyst Joseph Pantginis maintains BiomX (AMEX:PHGE) with a Buy and lowers the price target from $20 to $10.
BiomX Reports Results Of Phase 2 Cosmetic Acne Study Showed Statistically Significant Improvement From Baseline Observed In Appearance Of Acne-prone Skin But No Meaningful Difference Demonstrated Relative To Vehicle
BiomX Inc. (NYSE:PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage cocktails that target specific pathogenic bacteria, today
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal
Here's a roundup of top developments in the biotech space over the last 24 hours.
BiomX Q2 EPS $(0.30) Beats $(0.37) Estimate
BiomX (AMEX:PHGE) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.37) by 18.92 percent. This is a 11.11 percent decrease over losses of $(0.27) per share from the same
Earnings Scheduled For August 16, 2021
Companies Reporting Before The Bell
• Entera Bio (NASDAQ:ENTX) is likely to report earnings for its second quarter.
• Data Storage (NASDAQ:DTST) is expected to report earnings for its second quarter.
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning session, 77 companies made new 52-week lows.
BiomX Inc. Announces $15M Registered Direct Offering
BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced today